PF-06817024 is an anti-IL-33 monoclonal antibody; a phase I placebo-controlled trial in healthy subjects, patients with chronic nasal sinusitis, and patients with AD has been recently completed, with no evidence of serious adverse events [108]. The gene discussed is IL33; the disease is Alzheimer disease.